Open Access. Powered by Scholars. Published by Universities.®
Virginia Commonwealth University
AROMATASE INHIBITORS; DOUBLE-BLIND; CLINICAL-TRIAL; LIVE-BIRTH; PHASE-II; WOMEN; ANASTROZOLE; MULTICENTER; PREGNANCY; METFORMIN
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Letrozole Versus Clomiphene For Infertility In The Polycystic Ovary Syndrome, Richard S. Legro, Robert Bryzki, Michael Diamond, Christos Coutifaris, William D. Schlaff, Peter Casson, Gregory M. Christman, Hao Huang, Qingshang Yan, Ruben Alvero, Daniel J. Haisenleder, Kurt T. Barnhart, G. Wright Bates, Rebecca Usadi, Scott Lucidi, Valerie Baker, J. C. Trussell, Stephen A. Krawetz, Peter Snyder, Dana Ohl, Nanette Santoro, Esther Eisenberg, Heping Zhang
Letrozole Versus Clomiphene For Infertility In The Polycystic Ovary Syndrome, Richard S. Legro, Robert Bryzki, Michael Diamond, Christos Coutifaris, William D. Schlaff, Peter Casson, Gregory M. Christman, Hao Huang, Qingshang Yan, Ruben Alvero, Daniel J. Haisenleder, Kurt T. Barnhart, G. Wright Bates, Rebecca Usadi, Scott Lucidi, Valerie Baker, J. C. Trussell, Stephen A. Krawetz, Peter Snyder, Dana Ohl, Nanette Santoro, Esther Eisenberg, Heping Zhang
Obstetrics and Gynecology Publications
BACKGROUND
Clomiphene is the current first-line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, including letrozole, might result in better pregnancy outcomes.
METHODS
In this double-blind, multicenter trial, we randomly assigned 750 women, in a 1:1 ratio, to receive letrozole or clomiphene for up to five treatment cycles, with visits to determine ovulation and pregnancy, followed by tracking of pregnancies. The polycystic ovary syndrome was defined according to modified Rotterdam criteria (anovulation with either hyperandrogenism or polycystic ovaries). Participants were 18 to 40 years of age, had at least one patent fallopian …